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Abstract: 25 
 26 
Mammalian prions propagate by template-directed misfolding and aggregation of normal 27 
cellular prion related protein PrPC as it converts into disease-associated conformers 28 
collectively referred to as PrPSc. Mammalian species may be permissive for prion disease 29 
because these hosts have co-evolved specific co-factors that assist PrPC conformational 30 
change and prion propagation. We have tested this hypothesis by examining whether faithful 31 
prion propagation occurs in the normally PrPC -null invertebrate host Drosophila 32 
melanogaster. Ovine PrP transgenic Drosophila exposed at the larval stage to ovine scrapie 33 
showed a progressive accumulation of transmissible prions in adult flies. Strikingly, the 34 
biological properties of distinct ovine prion strains were maintained during their propagation 35 
in Drosophila. Our observations show that the co-factors necessary for strain-specific prion 36 
propagation are not unique to mammalian species. Our studies establish Drosophila as a 37 
novel host for the study of transmissible mammalian prions. 38 
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ARQ  A136R154Q171 ovine PrP 48 
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Introduction 61 
 62 
Mammalian prions cause fatal neurodegenerative diseases such as Creutzfeldt-Jakob disease 63 
(CJD) in humans, Bovine Spongiform Encephalopathy (BSE) in cattle and scrapie disease of 64 
sheep (Prusiner, 2004). These conditions are transmissible between individuals of the same or 65 
different species and as a consequence, animal prion diseases pose a realistic threat to human 66 
health through their zoonotic potential (Bruce et al., 1997). Prions lack a conventional nucleic 67 
acid-based genome. The ‘protein only’ concept that relates to prion diseases predicts that 68 
infectious prion particles consist of PrPSc in the form of aggregates of misfolded conformers 69 
of the normal host protein PrPC (Prusiner, 1982). Prion propagation occurs by template-70 
directed nucleation whereby a prion seed induces conformational change within PrPC and 71 
promotes the incorporation of nascent misfolded prion protein into growing PrPSc assemblies, 72 
which subsequently undergo fragmentation (Collinge, 2016).  73 
 74 
PrPC is a cell-surface glycoprotein attached to the membrane by a glycosylphosphatidyl 75 
inositol (GPI) anchor (Stahl et al., 1987). It is now well established that PrPC expression is 76 
obligatory for prion replication and prion-induced neurotoxicity (Bueler et al., 1993; Mallucci 77 
et al., 2003). A remarkable feature of mammalian prions is the existence of different strains of 78 
the transmissible agent that directly influence host range and the clinico-pathological features 79 
of prion disease in the affected host (Prusiner, 2004). According to the ‘protein only’ concept 80 
(Prusiner, 1982), prion strain-specific properties are dictated by the conformational 81 
arrangement of PrPSc (Bessen and Marsh, 1994; Safar et al., 1998; Telling et al., 1996). 82 
Changes in the replication environment of prions can induce mutational change in their strain 83 
properties (Collinge and Clarke, 2007), an event that may occur during inter-species prion 84 
transmission where PrP primary structures differ (Bartz et al., 2000; Kimberlin et al., 1987).  85 
 86 
Several fundamental features of mammalian prion biology remain unresolved despite 87 
considerable efforts aimed at their elucidation (Collinge, 2016). These include lack of a full 88 
description of the molecular and cellular machinery necessary to generate infectious 89 
neurotoxic prions (Supattapone, 2014). The possibility exists that mammalian hosts, in which 90 
PrPC is ubiquitously expressed and well conserved, are permissive for prion formation 91 
because they have co-evolved specific co-factors that assist in prion protein misfolding and 92 
propagation. Here we have tested this hypothesis by examining whether authentic prion 93 
propagation occurs in Drosophila melanogaster, an invertebrate species that is 94 
 4 
phylogenetically separated from mammals by millions of years of divergent evolution. 95 
Drosophila and other members of the arthropod phylum do not show the presence of an 96 
orthologous PrP gene in their genome and therefore do not normally express PrPC (Rivera-97 
Milla et al., 2006).  98 
 99 
In this study, we tested the capacity of mammalian prions to faithfully propagate in a strain-100 
specific manner in Drosophila genetically engineered to express PrPC (Thackray et al., 2012b; 101 
Thackray et al., 2014). Exposure of larval stage PrP transgenic Drosophila to mammalian 102 
prions resulted in a progressive accumulation of bona fide prions in adult flies. Strikingly, the 103 
biological properties of the original prion strain used as inoculum were maintained during 104 
their passage in the insect host. These observations show for the first time that the molecular 105 
and cellular co-factors necessary for strain-specific prion propagation are conserved between 106 
phylogenetically diverse species and are not unique to mammalian hosts. Our studies provide 107 
a fundamental advance in the understanding of mammalian prion biology and also establish 108 
Drosophila as a novel methodology for the study of transmissible mammalian prions.   109 
 110 
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Materials and Methods 116 
Fly stocks 117 
The UAS-PrP fly lines w; M{VRQ-PrP(GPI), 3xP3-RFP.attP}ZH-51D and w; M{ARQ-118 
PrP(GPI), 3xP3-RFP.attP}ZH-51D transgenic for ovine V136R154Q171 (VRQ) or A136R154Q171 119 
(ARQ) PrP, respectively, expressed with an N-terminal leader peptide and C-terminal GPI 120 
signal sequence, were generated by PhiC31 site-specific transformation by Bestgene 121 
(California, USA) as previously described (Thackray et al., 2012c). The following fly lines 122 
were obtained from the Department of Genetics, University of Cambridge, UK.  123 
Actin-5C-GAL4 (y w; P{w[+mC]=Act5C-Gal4}25F01/CyO, y[+]) 124 
Elav-GAL4 (P{w[+mW.hs]=GawB}elav[C155])  125 
51D (w; M{3xP3-RFP.attP}ZH-51D)  126 
Cre-mediated removal of the red fluorescent protein (RFP) gene from the VRQ and 51D fly 127 
genome was performed by conventional fly crosses (Thackray et al., 2014). PrP transgenic 128 
Drosophila were crossed with either the Elav-GAL4 or Actin-5C-GAL4 driver fly lines to 129 
derive transgenic flies that expressed PrP pan neuronally or ubiquitously, respectively. 51D 130 
Drosophila crossed with either driver fly line were used as control flies where appropriate. 131 
All fly lines were raised on standard cornmeal media at 25˚C and maintained at low to 132 
medium density, and pre-mated before experimental use.  133 
 134 
Prion inoculation of Drosophila 135 
Primary transmission of sheep scrapie (sheep-to-fly): Drosophila at the larval stage of 136 
development were exposed to brain homogenate of cerebral cortex tissue from a confirmed 137 
PG127 (alternatively referred to as DAW or G338) scrapie-positive sheep (SE1848/0005) 138 
(Thackray et al., 2008). New Zealand-derived VRQ/VRQ scrapie-free brain tissue was used 139 
as control material. Two hundred and fifty microlitres of a 1% (w/v) sheep brain homogenate 140 
prepared in PBS pH7.4, were added to the top of the cornmeal that contained third instar 141 
Drosophila larvae in 3-inch plastic vials. Following eclosion (i.e. hatching) flies were 142 
transferred to fresh non-treated vials. Secondary transmission of sheep scrapie (fly-to-fly): 143 
Drosophila head homogenates were prepared from 30 day old flies that had been exposed at 144 
the larval stage to scrapie-positive or scrapie-negative sheep brain material. Two hundred and 145 
fifty microlitres of a 10-1 (v/v) dilution of the original fly brain homogenate were added to the 146 
top of the cornmeal that contained third instar Drosophila larvae in 3-inch plastic vials. Flies 147 
were transferred to fresh, non-treated vials following eclosion. Transmission of defined ovine 148 
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prion strains in PrP transgenic Drosophila: Drosophila at the larval stage of development 149 
were exposed to 1% (w/v) mouse brain homogenate infected with a defined ovine prion strain 150 
or prion-free mouse brain homogenate as control. The different mouse-adapted prion strains 151 
used here were isolated by serial passage of sheep scrapie isolates in ovine PrP transgenic 152 
mice as previously described (Thackray et al., 2011; Thackray et al., 2012a).  153 
 154 
Preparation of Drosophila head homogenate  155 
Whole flies in an eppendorf tube were frozen in liquid nitrogen for 10 minutes and then 156 
vortexed for 2 minutes to cause decapitation. Individual fly heads were isolated and placed in 157 
clean eppendorf tubes using a fine paint brush. PBS pH7.4 was added to give 1µL / head and 158 
homogenates were prepared by manual grinding of the fly heads with sterilized plastic pestles. 159 
For western blot analysis, fly head homogenate was mixed with an equal volume of 20% 160 
scrapie-free sheep brain homogenate prior to extraction and PK digestion as previously 161 
described (Lacroux et al., 2012) using monoclonal antibody Sha31 (Feraudet et al., 2005). 162 
 163 
Protein misfolding cyclic amplification (PMCA)  164 
PMCA was carried out as previously described (Lacroux et al., 2012). The substrate consisted 165 
of 10% (w/v) ovine VRQ PrP transgenic mouse (tg338) brain homogenate in PBS pH 7.4, 166 
0.1% Triton X-100 and 150 mM NaCl buffer. Five µL of fly head homogenate were mixed 167 
with 45µL of substrate in 0.2 mL thin wall PCR tubes. Sealed tubes were then placed in the 168 
horn of a Misonix 4000 sonicator for one round of 96 cycles. Each cycle consisted of a 10 169 
second sonication step (70% of power) followed by a 14 minute and 50 second incubation 170 
step. Twenty µL of each reaction mix were subsequently treated with PK (4µg of PK per mg 171 
of protein) at 37°C for 2 hours and the reaction stopped by adding Pefabloc (4mM final 172 
concentration). PK-resistant PrP was detected by western blot as previously described 173 
(Lacroux et al., 2012) using monoclonal antibody Sha31 (Feraudet et al., 2005).  174 
 175 
Mouse prion bioassay 176 
Mouse prion bioassays were carried out in tg338 mice, which are transgenic for ovine VRQ 177 
PrP and are highly efficient for the detection of sheep scrapie infectivity (Le Dur et al., 2005). 178 
Mice (n=6 per inocula) were injected intracerebrally with 20µL of diluted fly head 179 
homogenate (to give approximately 2 fly head equivalents per mouse) and monitored daily 180 
until the occurrence of clinical signs of mouse prion disease. Inoculated mice were euthanized 181 
when they started to show locomotor disorders and any impairment in their capacity to feed, 182 
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or at a pre-defined end-point for the assay (either >250 days or in some cases >670 days post 183 
inoculation) (Andreoletti et al., 2011). Brain tissue (cerebral cortex) was collected from 184 
euthanized mice and frozen for PrPSc analysis by Western blot (TeSeE, BioRad) or PET blot 185 
analysis (Andreoletti et al., 2011).  186 
 187 
Negative geotaxis climbing assay  188 
The locomotor ability of flies was assessed in a negative geotaxis climbing assay initiated 189 
with 45 (3 x n=15) age-matched, pre-mated female flies in each treatment group. Drosophila 190 
were placed in adapted plastic 25mL pipettes that were used as vertical climbing columns and 191 
allowed to acclimatise for 30 minutes prior to assessment of their locomotor ability. Flies 192 
were tapped to the bottom of the pipette (using the same number and intensity of taps on each 193 
occasion) and then allowed to climb for 45 seconds. At the end of the climbing period the 194 
number of flies above the 25mL mark, the number below the 2mL mark and the number in 195 
between the 2mL and 25mL mark was recorded. This procedure was performed three times at 196 
each time point. The performance index (PI) was calculated for each group of 15 flies 197 
(average of 3 trials) using the formula: 198 
PI = 0.5 × (ntotal + ntop − nbottom)/ntotal where ntotal is the total number of flies, ntop is the 199 
total number of flies at the top, and nbottom is the total number of flies at the bottom. A PI 200 
value of 1 is recorded if all flies climb to the top of the tube whereas the value is 0 if no flies 201 
climb the tube past the 2mL mark. The mean PI ± SD at individual time points for each 202 
treatment group was plotted as a regression line.  203 
 204 
Statistical analysis 205 
Statistical analysis of the negative geotaxis climbing assay data was performed by the paired 206 
Student t test, using Prism (GraphPad Software Inc, San Diego, USA). 207 
 208 
 209 
210 
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Results 211 
 212 
Mammalian prions replicate in PrP transgenic Drosophila 213 
Transgenic Drosophila that express membrane-bound VRQ ovine PrP (VRQ Drosophila fly 214 
line) and control non-transgenic flies (51D fly line) were exposed at the larval stage to brain 215 
material prepared from either PG127 scrapie-infected or healthy prion-free sheep (Thackray 216 
et al., 2012c; Thackray et al., 2014). After hatching, Drosophila were transferred to prion-free 217 
culture tubes. At various time points (≤40 days) during their adult lifespan, groups of 218 
Drosophila were euthanized, decapitated and homogenate prepared from the isolated fly 219 
heads. These homogenates were used to seed in vitro PMCA reactions in order to reveal the 220 
presence of prion seeding activity as shown by the data in Figure 1. PMCA mimics prion 221 
replication in vivo, but in an accelerated form, allowing amplification of minute quantities of 222 
PrPSc and prion infectivity (Saborio et al., 2001). In PMCA reactions, a PrPC-containing 223 
substrate (in this study brain homogenate prepared from ovine PrP transgenic mice) is 224 
combined with the seed (in this study Drosophila head homogenate) that may contain minute 225 
amounts of PrPSc. Following repeated cycles of incubation and sonication, the amount of 226 
PrPSc seed increases to levels at which it can be detected by conventional biochemical means, 227 
such as western blot detection of PK-resistant PrPSc as was used here. 228 
 229 
No prion seeding activity was detected in PMCA reactions with seed prepared from mock-230 
infected VRQ Drosophila head homogenate, or from scrapie-exposed or mock-infected 51D 231 
control flies (Figure 1A). Similarly, no prion seeding activity was detected in head 232 
homogenates prepared from 5 or 10 day old scrapie-exposed VRQ Drosophila. Strikingly, 233 
prion seeding activity was detected in head homogenate prepared from scrapie-infected VRQ 234 
Drosophila aged ≥20 days. An end-point titration of prion seeding activity, carried out using 235 
serial 10-fold dilutions of original fly head homogenate, indicated a progressive increase of 236 
prion seeding titre in the heads of prion-exposed VRQ Drosophila from 20 to 40 days of age 237 
(Figure 1B). The seeding activity in 40 day old prion-exposed VRQ Drosophila was 10-4 238 
lower than that seen in a terminal disease-PG127 sheep scrapie inoculum (Thackray et al., 239 
2016). 240 
 241 
We determined if the presence of the prion seeding activity in scrapie-inoculated VRQ 242 
Drosophila was associated with the presence of PK-resistant PrPSc, a pathognomonic marker 243 
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of prion disease in mammalian hosts (Prusiner, 2004). Head homogenate from 40 day old 244 
Drosophila was PK-digested and analyzed directly by SDS-PAGE and western blot probed 245 
with an anti-PrP monoclonal antibody. The data in Figure 2 show that no PK-resistant PrPSc 246 
signal was detected in Drosophila exposed to scrapie-free sheep brain material (Figures 2A 247 
and 2B), or from scrapie-treated 51D flies (Figure 2C). Notably, a PK-resistant PrP signal was 248 
detected in head homogenate from scrapie-exposed VRQ Drosophila (Figure 2D). The 249 
molecular profile of the PK-resistant PrP in VRQ Drosophila was clearly different to that 250 
present in the original PG127 inoculum, an expected feature considering differences in N-251 
linked glycosylation that exists between Drosophila and mammalian hosts (Choi et al., 2010; 252 
Thackray et al., 2012c). The intensity of the PK-resistant PrP signal in the VRQ Drosophila 253 
head homogenate was similar to that obtained in a 10-4 dilution of a terminal disease-PG127 254 
sheep scrapie inoculum. This result was consistent with the data obtained in the PMCA end 255 
point titration where 40 day old VRQ Drosophila displayed a 10-4 lower seeding activity than 256 
a terminal disease-PG127 scrapie inoculum.  257 
 258 
Fly-to-mouse prion transmission 259 
In order to unequivocally demonstrate that authentic prions replicated in scrapie-exposed 260 
VRQ Drosophila we performed fly-to-mouse transmission. Head homogenate from flies used 261 
as a seed in the PMCA experiment shown above was inoculated into ovine VRQ PrP 262 
transgenic (tg338) mice. The transmission data are shown in Table 1. No evidence of clinical 263 
prion disease or abnormal PrP accumulation were observed in mice inoculated with head 264 
homogenates prepared from VRQ Drosophila and 51D flies exposed to control sheep brain 265 
homogenate. Similarly, no prion infectivity was detected in tg338 mice inoculated with head 266 
homogenates prepared from 5 or 10 day old PG127-exposed VRQ Drosophila. An incomplete 267 
attack rate for clinical prion disease transmission was observed in tg338 mice inoculated with 268 
head homogenate from 20 day old scrapie-infected VRQ Drosophila. Mice inoculated with 269 
head homogenates prepared from 30 and 40 day old scrapie-exposed VRQ Drosophila 270 
developed a 100% attack rate for clinical prion disease transmission. The brains of tg338 mice 271 
inoculated with fly-head homogenate were probed for disease-associated PrP as shown by the 272 
data in Figure 3. Prion disease in mice that showed clinical signs of the condition was 273 
confirmed by western blot detection of PK-resistant PrPSc (Figure 3A). PET blot analysis of 274 
the brains of clinically affected mice showed the typical distribution of PrPSc in PG127 275 
scrapie-inoculated tg338 mice (Figure 3B). No clinical signs of mouse prion disease or 276 
abnormal PrP accumulation were observed in tg338 mice inoculated with scrapie-exposed 277 
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51D fly head homogenate. This result excludes the suggestion that carry-over of the original 278 
sheep inoculum was an explanation for prion infectivity detection in scrapie-exposed VRQ 279 
Drosophila. 280 
 281 
To further increase the robustness of this observation, the fly-to-mouse transmission 282 
experiment was repeated twice using samples obtained in two independent experiments (using 283 
the same fly lines and the same sheep scrapie prion strain). Supplementary Data S1 shows 284 
that the observed incubation times and attack rates in these repeat experiments were 285 
consistent to those recorded in the original experiment. Collectively these data unequivocally 286 
demonstrate that ovine prion infectivity progressively accumulated in scrapie-exposed ovine 287 
VRQ PrP transgenic Drosophila.  288 
 289 
Fly-to-Fly prion propagation 290 
We next investigated whether the prion infectivity that accumulates in VRQ Drosophila at 291 
first passage could be serially propagated in the same fly line. Accordingly, head homogenate 292 
from 30 day old adult Drosophila (first passage flies) was used to inoculate fresh VRQ 293 
Drosophila (second passage flies) at the larval stage. Second passage VRQ Drosophila were 294 
allowed to hatch and groups of flies were euthanized at 5, 30 and 40 days of age when head 295 
homogenate was prepared for PMCA analysis. The data in Supplementary Data S2 show, as 296 
expected, no PMCA prion seeding activity was detected in VRQ Drosophila that were 297 
exposed to head homogenate from first passage mock-infected VRQ Drosophila, or first 298 
passage scrapie- or mock infected 51D flies. However, prion seeding activity was detected in 299 
second passage VRQ Drosophila exposed to 30 and 40 day old, but not 5 day old, head 300 
homogenate from first passage scrapie-exposed VRQ Drosophila. Endpoint titration of the 301 
PMCA-positive second passage VRQ Drosophila samples indicated an increase in prion 302 
seeding activity titre in these flies between 30 and 40 days of age.  303 
 304 
Second passage VRQ Drosophila head homogenate was inoculated into tg338 mice in order 305 
to assess prion infectivity in these samples. Mice that received 30 day old PMCA-positive 306 
second passage VRQ Drosophila head homogenate showed 100% attack rate for clinical 307 
signs of mouse prion disease and an incubation period of 89±4 days. The brains of inoculated 308 
mice were examined for the presence of  disease-associated PrP as shown by the data in 309 
Supplementary Data S3. PK-resistant PrPSc was evidenced by western blot of the brains of 310 
clinically affected mice and PET blot analysis of the brains of clinically affected mice 311 
 11 
revealed the typical distribution of PrPSc in PG127 scrapie-inoculated tg338 mice. No clinical 312 
signs or abnormal PrP accumulation was observed in tg338 mice inoculated with 5 day old 313 
second passage VRQ Drosophila head homogenate or from VRQ Drosophila exposed to first 314 
passage 51D control flies. These results demonstrate that mammalian prions propagated in 315 
VRQ Drosophila can be serially transmitted in flies.  316 
 317 
Prion-induced toxic phenotype in PrP transgenic Drosophila 318 
Since prion-induced toxicity occurs concomitantly with prion replication in mammalian hosts 319 
(Bueler et al., 1993; Mallucci et al., 2003) we next investigated whether the propagation of 320 
prions in VRQ Drosophila induced a toxic phenotype in these flies. To do so, we performed a 321 
negative geotaxis climbing assay (Thackray et al., 2012c) using adult Drosophila previously 322 
exposed at the larval stage to ovine scrapie prions. The data in Supplementary S4 (together 323 
with the accompanying statistical analysis described in the Supplementary Materials for this 324 
figure) show that there was no difference in the climbing ability between 51D flies exposed to 325 
PG127 scrapie or control prion-free sheep brain homogenate. Strikingly, VRQ Drosophila 326 
developed a toxic phenotype after exposure to PG127 prions, evidenced by an accelerated 327 
decrease in locomotor ability compared to control treated flies, that became progressively 328 
more severe with age. Collectively, these data show that the prion-induced toxic fly 329 
phenotype was associated with prion propagation in adult PrP transgenic Drosophila as 330 
evidenced by the data in Table 1 and Figure 3. 331 
 332 
Prion strain properties are maintained in PrP transgenic Drosophila  333 
A comparison of the incubation period and PK-resistant PrPSc molecular profile observed in 334 
tg338 mice inoculated with either a sample of the original PG127 sheep scrapie inoculum, or 335 
this material passaged in VRQ Drosophila, suggested that mammalian prion strain properties 336 
were unaltered following propagation in PrP transgenic Drosophila. To confirm this was the 337 
case we propagated three distinct ovine prion strains in PrP transgenic Drosophila prior to 338 
their re-isolation in tg338 mice. The panel of ovine prion strains used here have been 339 
previously characterized by bioassay in tg338 mice and are differentiated by unique 340 
incubation times and on the basis of their PK-resistant PrPSc western blot molecular profile 341 
(Thackray et al., 2011; Thackray et al., 2012a). We exposed ovine PrP transgenic Drosophila 342 
at the larval stage to each ovine scrapie prion strain. VRQ Drosophila were exposed to ovine 343 
prions isolated in VRQ PrP transgenic mice and ARQ Drosophila were exposed to ovine 344 
prions isolated in ARQ PrP transgenic mice. Collectively, the ovine PrP transgenic 345 
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Drosophila were susceptible to all three different prion strains shown by the development of a 346 
progressive toxic phenotype in the form of an accelerated decline in performance in a 347 
negative geotaxis climbing assay (see Supplementary Data S4).  348 
 349 
An aliquot of each original prion strain isolated in PrP transgenic mice and samples of these 350 
prions propagated in PrP transgenic Drosophila were transmitted to tg338 mice (for either one 351 
or two passages). The attack rate and incubation period observed in tg338 mice inoculated 352 
with the original prion strains were similar to those obtained following inoculation with the 353 
equivalent prion strain propagated in PrP transgenic Drosophila as shown by the data in Table 354 
2. The brains of clinically prion-diseased tg338 mice were examined for disease-associated 355 
PrP and neuropathology as shown by the data in Figure 4. Irrespective of the number of 356 
passages, the molecular profile of PK-resistant PrPSc observed in the brains of tg338 mice 357 
inoculated with the original ovine prions and those propagated in PrP transgenic Drosophila 358 
were indistinguishable (Figure 4A). In addition, the vacuolar lesion profile in the brains of 359 
tg338 mice inoculated with the original ovine prion strain and with the equivalent prion strain 360 
propagated in PrP transgenic Drosophila were virtually identical (Figure 4B). Collectively, 361 
these data demonstrate that the biological properties of distinct ovine prion strains were 362 
maintained after their propagation in ovine PrP transgenic Drosophila.  363 
364 
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Discussion 365 
 366 
In our study presented here we have demonstrated that scrapie-exposed Drosophila transgenic 367 
for ovine PrP expressed pan neuronally displayed a progressive accumulation of prion 368 
seeding activity and showed the presence of PK-resistant PrP. Crucially, we also 369 
demonstrated a progressive accumulation of prion infectivity in these Drosophila by bioassay 370 
in tg338 mice. These features unequivocally demonstrate for the first time the replication of 371 
bona fide mammalian prions in a PrP transgenic invertebrate host. 372 
 373 
The central role of PrP in prion replication has been verified by infectivity studies in 374 
mammalian hosts, principally mice, with either gene knock-out or transgenic over-expression 375 
of endogenous prion protein expression (Brandner and Jaunmuktane, 2017). These extensive 376 
studies have collectively established that mammalian prions do not replicate in hosts that fail 377 
to express PrPC. However, several lines of evidence have suggested that expression of 378 
PrPC alone is not sufficient to confer susceptibility to prion propagation (Courageot et al., 379 
2008; Enari et al., 2001; Raeber et al., 1999). This has led to the suggestion that specific 380 
molecular co-factors and/or cellular machinery are crucial for prion propagation. The nature 381 
and function of co-factors in prion propagation remains undefined (Ma, 2012), although their 382 
role is highlighted by in vitro reconstitution experiments. To date, RNA or lipid has been 383 
shown to be required for the generation of prions with high infectious titre (Deleault et al., 384 
2003; Deleault et al., 2012; Wang et al., 2010). However, it is possible that other molecular 385 
components participate in the process of prion replication and the definitive list of these co-386 
factors and their mode of action remain to be established (Castilla et al., 2008). Insects are 387 
invertebrate hosts that are phylogenetically separated in evolutionary terms from mammals by 388 
millions of years. We have demonstrated here that Drosophila, a normally PrP-null insect 389 
host, rendered transgenic solely for mammalian PrP, are permissive for the faithful replication 390 
of a panel of three mammalian prion strains. This provides a cogent argument that the nature 391 
of the molecular and cellular factors that facilitate prion replication do not result from a co-392 
evolutionary selection process between the infectious agent and their natural hosts. 393 
 394 
An intriguing feature in mammalian prion biology is the existence of prion strains. These are 395 
identified as different prion isolates from individuals of the same species that produce distinct 396 
disease phenotypes upon serial passage in isogenic hosts (Bruce and Dickinson, 1987). 397 
Glycosylation is an important factor in the determination and maintenance of conformation, 398 
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function and interactions of glycoproteins (O'Connor and Imperiali, 1996). Mammalian PrP 399 
expressed in the natural host has two N-linked carbohydrate moieties attached to asparagine 400 
residues located in the C-terminal domain of the protein (Endo et al., 1989). Transmission 401 
experiments carried out in mice transgenic for PrP devoid of either one or both N-linked 402 
carbohydrate moieties, as a result of changes to the prion protein primary structure, indicated 403 
an alteration in the biological properties of some of the prion strains tested (Cancellotti et al., 404 
2013). These results supported the view that N-linked glycosylation of PrPC could participate 405 
in the transfer and/or maintenance of the prion strain-specific information. Mammalian N-406 
linked glycoproteins, including those attached to PrPC expressed in the natural host, typically 407 
comprise complex glycans that consist of N-acetylglucosamine (GlcNAc), mannose, 408 
galactose, and terminal sialic acid residues (Endo et al., 1989). In contrast, the majority of 409 
neurones in the Drosophila brain synthesise N-linked glycans with core structures similar or 410 
identical to those produced by all eukaryotes but fail to acquire complex carbohydrate 411 
structures (März et al., 1995). Our study here demonstrates that the biological properties of 412 
distinct ovine prion strains were maintained after propagation in PrP transgenic Drosophila. 413 
Therefore, differences in N-linked glycosylation moieties between mammalian and insect 414 
species had no apparent impact on the biological properties of the different prion strains that 415 
we propagated in PrP transgenic Drosophila. 416 
 417 
We have shown that VRQ Drosophila exposed to scrapie prions at the larval stage show an 418 
accelerated decline in locomotor ability at adulthood (Thackray et al., 2012b; Thackray et al., 419 
2014; Thackray et al., 2016). The severity of this prion-induced toxic fly phenotype increased 420 
as the flies aged and correlates with the accumulation of prion seeding activity and infectivity 421 
in PrP transgenic Drosophila. In mammalian species clinical signs in prion affected 422 
individuals arise as a consequence of neurodegenerative processes initiated by the conversion 423 
of PrPC to PrPSc. Only cells that express PrPC are susceptible to prion-induced toxicity and 424 
formation of the toxic moiety occurs concomitantly with prion replication (Bueler et al., 1993; 425 
Mallucci et al., 2003). Despite significant advances (Moreno et al., 2012), the mechanisms 426 
responsible for neurodegeneration in prion disease and the role of PrPC and PrPSc remain 427 
incompletely defined. Unravelling events that are directly triggered by prion protein 428 
conversion from those arising as a consequence of the perturbation of the central nervous 429 
system micro-environment is extremely challenging. PrP was expressed pan neuronally in the 430 
VRQ PrP transgenic fly line used to assess prion seeding activity and prion infectivity in the 431 
scrapie-infected Drosophila we have used here. We have previously shown that a prion-432 
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induced toxic phenotype occurs in Drosophila transgenic for pan neuronal expression of PrP 433 
(Thackray et al., 2014; Thackray et al., 2016). Consequently, we consider that the prion-434 
induced decline of the locomotor activity observed in PrP transgenic Drosophila reflects a 435 
neurotoxic phenotype that arises as a consequence of prion replication. This supports the view 436 
that PrP transgenic Drosophila can serve as a tractable system to probe for genetic modifiers 437 
of prion-induced neurodegeneration. Drosophila are increasingly used as a model system in 438 
the study of mammalian neurodegenerative disease including the pathobiology of Alzheimer’s 439 
disease, Parkinson’s disease and tauopathies (Lu and Vogel, 2009). This arises because the 440 
brains of Drosophila and mammalian species are composed of similar components (i.e. 441 
neurons and neuronal circuitry), and the nature of ion channels, neurotransmitters and 442 
synaptic proteins are highly conserved between mammals and the fly (Lessing and Bonini, 443 
2009). Our use of PrP transgenic Drosophila to recapitulate mammalian prion infection 444 
provides an unprecedented opportunity to unravel the mechanisms of prion-induced 445 
neurotoxicity in a new animal system. Drosophila have already proved to be an important 446 
animal model to analyse the genetics of mammalian neurodegeneration. For example, 447 
resultant behavioural defects in Drosophila that arise through the deletion of a fly homolog of 448 
a human neurodegenerative gene can be compensated for by a functional human homologous 449 
gene (Luo et al., 1992). In addition, mutagenesis screens in Drosophila have led to the 450 
isolation of flies that show late-onset progressive degeneration of the adult nervous system 451 
that resembles human diseases (Min and Benzer, 1999). 452 
 453 
Prion bioassays, which are generally carried out in conventional or transgenic mice, or 454 
primates or small ruminants, continue to provide a central role in the study of mammalian 455 
prion diseases. However, because of ethical and economic reasons, such as the cost of 456 
maintaining the vertebrate species during long bioassays, there is increasing pressure to limit 457 
their use and adopt alternative approaches to assess mammalian prion infectivity. Over the 458 
last decade, in vivo prion biology studies have been supplemented by in vitro techniques such 459 
as PMCA (Saa et al., 2005) and quaking-induced conversion (QuIC) (Atarashi et al., 2007). 460 
Both of these methodologies have been used for the detection of prion seeding activity, a 461 
biochemically and biologically relevant surrogate marker of prion infectivity. In this context, 462 
PMCA and QuIC provide rapid and sensitive quantitative detection of prion-infected samples. 463 
However, in vitro amplification methods remain refractory to many questions and 464 
experimental needs that require to be addressed in prion research. These methods are also 465 
obviously not adapted for investigating prion-induced neurodegeneration. Drosophila have 466 
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several important positive experimental advantages as an animal model to study 467 
neurodegenerative disease. Large numbers of flies can be produced in a short time, which 468 
correlated with their relatively short life span and simple genetics, allow rapid, statistically 469 
robust data collection. The ability of Drosophila to faithfully propagate mammalian prion 470 
strains has multiple potential applications. In relation to prion diagnostics, our Drosophila-471 
based prion bioassay has already been shown to be capable of the sensitive detection of prion 472 
infectivity in brain tissue (Thackray et al., 2012b; Thackray et al., 2016) and blood (Thackray 473 
et al., 2016). PrP transgenic Drosophila could also help to address the need for new animal 474 
models that allow a relevant, rapid, robust and reasonably high throughput screening of 475 
therapeutic compounds against prion disease. 476 
 477 
In our studies presented here we have demonstrated that core features of transmissible 478 
mammalian prion disease can be re-capitulated in PrP transgenic Drosophila. This opens a 479 
new era for the investigation of prion-induced neurotoxicity and prion replication mechanisms 480 
in a genetically well-defined tractable animal system. This new invertebrate model of 481 
mammalian prion disease will provide the opportunity to exploit the power of genetics in the 482 
fly to identify potential genetic modifiers of prion-induced neurotoxicity. Such genetic 483 
modifiers may serve as candidate diagnostic markers or therapeutic targets of human prion 484 
disease and prion-like diseases. In addition, the ease of transgenesis in Drosophila will allow 485 
the development of fly lines that express different species forms of PrP, such as bovine, 486 
cervid and human PrP to bioassay prion infectivity from these different mammalian hosts. For 487 
appropriate biosecurity, these future studies will require the BSE, CWD or CJD-inoculated 488 
Drosophila to be maintained at containment level 3 for prion research, an enhanced level of 489 
safety above the containment level 2 used for the sheep scrapie studies described here. In this 490 
manner, PrP transgenic Drosophila can be used to begin to address important questions on the 491 
pathogenic potential of known and possible zoonotic prions. 492 
 493 
 494 
 495 
 496 
 497 
 498 
 499 
 500 
 501 
 502 
 503 
 504 
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Legends 505 
 506 
Figure 1. Prion seeding activity in scrapie-exposed PrP transgenic Drosophila 507 
Elav x VRQ(GPI) PrP transgenic (VRQ) and Elav x 51D (51D) Drosophila were exposed at 508 
the larval stage to PG127 scrapie-infected or prion-free control sheep brain material. At 509 
various times after hatching, head homogenate was prepared from harvested flies and used as 510 
seed in PMCA reactions. (A) End-point titration of PMCA prion seeding activity in head 511 
homogenate from control or PG127-exposed Drosophila; (B) Western blot detection of PK-512 
resistant PrP27–30 in PMCA reaction products seeded with control or PG127-exposed 513 
Drosophila head homogenate. Molecular mass markers in kDa shown on the left. 514 
 515 
Figure 2. PK-resistant PrP in scrapie-exposed PrP transgenic Drosophila 516 
Elav x VRQ(GPI) PrP transgenic (VRQ) and Elav x 51D (51D) Drosophila were exposed at 517 
the larval stage to PG127 scrapie-infected or prion-free control sheep brain material. At 30 518 
days post-hatching, head homogenate was prepared from harvested flies, treated with PK and 519 
analysed by western blot to detect PK-resistant PrP. (A) and (B) Drosophila exposed to 520 
control brain homogenate; (C) and (D) Drosophila exposed to PG127 scrapie-infected sheep 521 
brain homogenate; (A) and (C) Elav x 51D Drosophila; (B) and (D) Elav x VRQ(GPI) PrP 522 
transgenic Drosophila. A titration of original PG127 scrapie-infected sheep brain homogenate 523 
is included on each blot for comparative purposes. Molecular mass markers in kDa shown in 524 
the middle of the Figure. 525 
 526 
Table 1. Prion infectivity accumulates in scrapie-exposed PrP transgenic 527 
Drosophila  528 
Elav x VRQ(GPI) PrP transgenic (VRQ) and Elav x 51D (51D) Drosophila were exposed at 529 
the larval stage to PG127 scrapie-infected or prion-free control sheep brain material. At 530 
various times after hatching, head homogenate was prepared from harvested flies and 531 
intracerebrally inoculated into ovine PrP transgenic (tg338) mice. Inoculated mice were 532 
euthanized when they showed clinical signs of prion infection or after 250 days for those that 533 
did not develop clinical disease. Mice were considered positive for prion disease when PK-534 
resistant PrP27–30 was detected in brain tissue by western blot. The attack rate (number of 535 
prion positive mice/total number of mice inoculated) is reported for each treatment group. The 536 
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incubation period (IP) for inoculated mice, which represents the average time from 537 
inoculation to euthanasia for each inoculated group of animals, is reported in days ± SD.  538 
 539 
Figure 3. Detection of prion infectivity in scrapie-exposed PrP transgenic 540 
Drosophila 541 
Elav x VRQ(GPI) PrP transgenic (VRQ) and Elav x 51D (51D) Drosophila were exposed at 542 
the larval stage to PG127 scrapie-infected or prion-free control sheep brain material. At 543 
various times after hatching, head homogenate was prepared from harvested flies and 544 
inoculated into tg338 mice. Inoculated mice were euthanized when they showed clinical signs 545 
of prion infection or after 250 days for those that did not develop clinical disease. Mice were 546 
considered positive for prion disease when PK-resistant PrP27–30 was detected in brain tissue 547 
by western blot. (A) Western blot detection of PK-resistant PrP27–30 in the brains of tg338 548 
mice with clinical prion disease. Molecular mass markers in kDa shown on the right; (B) PET 549 
blot analysis of tg338 mouse brains from animals inoculated with 40 day old Elav x 550 
VRQ(GPI) PrP transgenic (VRQ) or Elav x 51D (51D) Drosophila exposed to PG127 551 
scrapie-infected or prion-free control sheep brain material. Scale bar represents 150 µm.  552 
 553 
Table 2: Scrapie strains retain transmission properties after passage in PrP 554 
transgenic Drosophila 555 
The ovine classical scrapie prion strains PG127 and Apl338 (isolated in ovine VRQ tg338 556 
mice) and Pa59 (isolated in ovine ARQ tg59 mice) were transmitted to tg338 ovine PrP 557 
transgenic mice. The ovine classical scrapie prion strains PG127, Pa59 or Apl338 were 558 
transmitted to tg338 ovine PrP transgenic mice. In parallel, Actin x VRQ(GPI) PrP transgenic 559 
(VRQ) Drosophila were exposed to the PG127 and Apl338, prion strains, and Elav x 560 
ARQ(GPI) PrP transgenic (ARQ) Drosophila were exposed to the Pa59 prion strain, at the 561 
larval stage. Head homogenates were prepared from adult flies aged 30 days and serially 562 
transmitted in tg338 mice (two iterative passages) by intracerebral inoculation. Mice were 563 
euthanized when they showed clinical signs of prion infection and after 250 days for those 564 
that did not develop clinical disease. Mice were considered positive for prion disease when 565 
PK-resistant PrP27–30 was detected in brain tissue by western blot. The attack rate (number 566 
of prion positive mice/total number of mice inoculated) is reported for each treatment group. 567 
The incubation period (IP) for inoculated mice, which represents the mean time from 568 
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inoculation to euthanazia for each inoculated group of animals, is reported in days ± SD. (NA: 569 
data not available, still ongoing).   570 
 571 
Figure 4. Authentic prion replication in PrP transgenic Drosophila 572 
Actin x VRQ(GPI) PrP transgenic (VRQ) Drosophila were exposed to the PG127 and Apl338, 573 
prion strains, and Elav x ARQ(GPI) PrP transgenic (ARQ) Drosophila were exposed to the 574 
Pa59 prion strain, at the larval stage. Actin x 51D and Elav x 51D (both referred to as 51D in 575 
appropriate graph) Drosophila were used as control flies where appropriate. Head 576 
homogenates were prepared from adult flies aged 30 days and inoculated into tg338 mice. 577 
Inoculated mice were euthanized when they showed clinical signs of prion infection or after 578 
250 days for those that did not develop clinical disease. Mice were considered positive for 579 
prion disease when PK-resistant PrP27–30 was detected in brain tissue by western blot. 580 
Mouse brains were analyzed for the presence of PK-resistant PrP and subjected to 581 
neuropathological assessment by PET blot and lesion profile analysis. (A) Western blot 582 
detection of PK-resistant PrP27–30 in the brains of tg338 mice during the isolation of PG127, 583 
Pa59 or Apl338, or prion strains (original inoculum), or these prion strains after passage in 584 
Drosophila (Drosophila passaged). Molecular mass markers in kDa are shown on the left; (B) 585 
PET blot and lesion profile analysis of tg338 mouse brains after exposure to the original 586 
mouse-derived PG127, Pa59 or Apl338, or prion strains (original inoculum), or these prion 587 
strains after passage in Drosophila (Drosophila passaged). Scale bar represents 150 µm.  588 
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Supplementary Materials: Mammalian prion propagation in PrP 599 
transgenic Drosophila  600 
 601 
Introduction 602 
We have successfully demonstrated that transmissible prions replicate in scrapie-exposed 603 
ovine PrP transgenic Drosophila (see main paper). In order to establish the robustness of our 604 
observations we performed repeat fly-to-mouse transmission experiments. We also 605 
investigated whether the prions that replicate in scrapie-exposed Drosophila were serially 606 
transmissible in the same fly line.  In addition, we investigated whether prion replication in 607 
the fly was associated with prion-induced toxic phenotype as assessed by a negative geotaxis 608 
climbing assay. 609 
 610 
Results and Discussion 611 
The data in Supplementary S1 show the attack rate (number of prion positive mice/total 612 
number of mice inoculated) and incubation period (IP) for repeat fly-mouse prion 613 
transmission experiments were similar to those observed in the original experiment shown in 614 
Table 1 of the main text. Collectively these data unequivocally demonstrate that ovine prion 615 
infectivity progressively accumulated in scrapie-exposed ovine VRQ PrP transgenic 616 
Drosophila.  617 
 618 
The data in Supplementary S2 show that the prion seeding activity that accumulates in 619 
scrapie-exposed VRQ Drosophila at first passage could be serially propagated in the same fly 620 
line. No PMCA prion seeding activity was detected in VRQ Drosophila exposed to head 621 
homogenate from first passage mock-infected VRQ Drosophila, or first passage scrapie- or 622 
mock infected 51D flies. Prion seeding activity was detected in second passage VRQ 623 
Drosophila exposed to 30 and 40 day old, but not 5 day old, head homogenate from first 624 
passage scrapie-exposed VRQ Drosophila. Endpoint titration of the PMCA-positive second 625 
passage VRQ Drosophila samples indicated an increase in prion seeding activity titre in these 626 
flies between 30 and 40 days of age. These data demonstrate fly-to-fly prion propagation. 627 
 628 
Second passage VRQ Drosophila head homogenate was inoculated into tg338 mice in order 629 
to assess the level of prion infectivity in these samples. Mice that received 30 day old PMCA-630 
positive second passage VRQ Drosophila head homogenate showed 100% attack rate for 631 
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clinical signs of mouse prion disease and an incubation period of 89±4 days. The brains of 632 
inoculated mice were examined for the presence of disease-associated PrP as shown by 633 
Supplementary S3. PK-resistant PrPSc was evidenced by western blot in the brains of 634 
clinically affected mice (Supplementary S3A). PET blot analysis of the brains of clinically 635 
affected mice showed the typical distribution of PrPSc in PG127 scrapie-inoculated tg338 636 
mice (Supplementary S3B). No clinical signs or abnormal PrP accumulation was observed in 637 
tg338 mice inoculated with 5 day old positive second passage VRQ Drosophila head 638 
homogenate or from VRQ Drosophila exposed to first passage 51D control flies. These 639 
results demonstrate that mammalian prions propagated in VRQ Drosophila can be serially 640 
transmitted in flies.  641 
 642 
We investigated whether prion replication in scrapie-exposed PrP transgenic Drosophila 643 
induced a toxic phenotype in these flies. To do so, PrP transgenic Drosophila were exposed at 644 
the larval stage to prion-infected or prion-free tg338 or tg59 mouse brain homogenate. After 645 
hatching, the locomotor ability of prion-exposed and control Drosophila, expressed as a 646 
performance index, was assessed by a negative geotaxis climbing assay (Thackray et al., 647 
2012c). The data in Supplementary S4 show the locomotor ability of adult Drosophila after 648 
exposure to ovine prions at the larval stage. Supplementary S4A shows that VRQ Drosophila 649 
displayed an accelerated decline in locomotor activity after exposure to both Apl338 and 650 
PG127 prion strains, which was significantly different to the response seen by that of similar 651 
flies exposed to scrapie-free tg338 mouse brain homogenate (p=0.0001, and p=0.0008, 652 
respectively, assessed over days 1 - 40). The data in Supplementary S4B show that the 653 
locomotor ability of ARQ Drosophila after exposure to Pa59 prions displayed a decline in 654 
locomotor activity that was significantly different to the response seen by that of similar flies 655 
exposed to scrapie-free mouse brain homogenate (p=0.0006, assessed over days 1 - 40). In 656 
contrast to these data, Supplementary S4C shows that control 51D flies displayed no 657 
difference in their locomotor ability after exposure to prion-infected or scrapie-free mouse 658 
brain homogenate (p>0.05 in all cases, except Apl338 p=0.0227, assessed over days 1 - 40). 659 
Collectively, these data show that PrP transgenic Drosophila are sensitive to prion-induced 660 
toxicity mediated by different prion strains.  661 
 662 
 663 
 664 
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Supplementary Data Legends 665 
 666 
Supplementary S1: Reproducible fly-to-mouse transmission of prions from 667 
scrapie-exposed PrP transgenic Drosophila 668 
Elav x VRQ(GPI) PrP transgenic (VRQ) and Elav x 51D (51D) Drosophila were exposed at 669 
the larval stage to PG127 scrapie-infected or prion-free control sheep brain material. At 30 670 
days post hatching, head homogenate was prepared from harvested flies and inoculated into 671 
tg338 mice. Mice were euthanized when they showed clinical signs of prion infection and 672 
after 250 or 670 days post-inoculation for those that did not develop clinical disease. Mice 673 
were considered positive for prion disease when PK-resistant PrP27–30 was detected in brain 674 
tissue by western blot. The attack rate (number of prion positive mice/total number of mice 675 
inoculated) is reported for each treatment group. The incubation period (IP) for inoculated 676 
mice, which represents the average time from inoculation to euthanasia for each inoculated 677 
group of animals, is reported in days ± SD.  678 
 679 
Supplementary S2. Serial transmission of prion seeding activity in scrapie-680 
exposed PrP transgenic Drosophila 681 
PG127 scrapie-infected or control prion-free sheep material was passaged in Elav x 682 
VRQ(GPI) PrP transgenic (VRQ) and Elav x 51D (51D) Drosophila (primary passage) and 683 
subsequently in Elav x VRQ(GPI) PrP transgenic (VRQ) flies (secondary passage). At 684 
various times after hatching, head homogenate was prepared from harvested flies and used as 685 
seed in PMCA reactions. (A) End-point titration of PMCA prion seeding activity in head 686 
homogenate from control or PG127-exposed Drosophila; (B) western blot analysis of PK-687 
resistant PrP27–30 in PMCA reaction products seeded with Drosophila head homogenate. 688 
Molecular mass markers in kDa are shown on the left. 689 
 690 
Supplementary S3. Serial transmission of prion infectivity in scrapie-exposed PrP 691 
transgenic Drosophila 692 
PG127 scrapie-infected or control prion-free sheep material was passaged in Elav x 693 
VRQ(GPI) PrP transgenic (VRQ) and Elav x 51D (51D) Drosophila (primary passage) and 694 
subsequently in Elav x VRQ(GPI) PrP transgenic (VRQ) flies (secondary passage). Head 695 
homogenate from second passage Elav x VRQ(GPI) PrP transgenic (VRQ) Drosophila was 696 
inoculated into tg338 mice. Inoculated mice were euthanized when they showed clinical signs 697 
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of prion infection or after 250 days for those that did not develop clinical disease. Mice were 698 
considered positive for prion disease when PK-resistant PrP27–30 was detected in brain tissue 699 
by western blot. (A) Western blot detection of PK-resistant PrP27–30 in the brains of tg338 700 
mice with clinical prion disease. Molecular mass markers in kDa are shown on the right; (B) 701 
PET blot analysis of the brains from tg338 mice inoculated with 30 day old 2nd passage Elav x 702 
VRQ(GPI) PrP transgenic (VRQ) Drosophila. Scale bar represents 150 µm.  703 
 704 
Supplementary S4. Prion-induced toxicity in scrapie-exposed PrP transgenic 705 
Drosophila 706 
Drosophila were assessed for their locomotor ability by a negative geotaxis climbing assay 707 
following exposure at the larval stage to PG127 (red line), Apl338 (light blue line); Pa59 (green 708 
line) prion-infected, or prion-free tg338 (grey line) or tg59 (black line) ovine PrP transgenic 709 
mouse brain homogenate. The data shown are linear regression plots of the mean performance 710 
index ± SD for three groups of flies per time point calculated as described in the Materials 711 
and Methods. p values assessed over days 1 – 40 of the climbing assay are shown on 712 
individual graphs. (A) Actin x VRQ(GPI) PrP transgenic (VRQ) Drosophila; (B) Elav x 713 
ARQ(GPI) PrP transgenic (ARQ) Drosophila; (C) Actin x 51D (green and black lines) and 714 
Elav x 51D (blue, red and grey lines).  715 
 716 
 717 
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Figure 1. Prion seeding activity in scrapie-exposed PrP transgenic Drosophila
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Figure 2. PK-resistant PrP in scrapie-exposed PrP transgenic Drosophila
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Table 1: Prion infectivity accumulates in scrapie-exposed PrP transgenic Drosophila
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Figure 3. Detection of prion infectivity in scrapie-exposed PrP transgenic Drosophila
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Table 2: Scrapie strains retain transmission properties after passage in PrP transgenic Drosophila
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Figure 4. Authentic prion replication in PrP transgenic Drosophila
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Supplementary Data S3. Serial transmission of prion infectivity in scrapie-exposed 
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Supplementary Data S4: Prion-induced  toxicity in scrapie-exposed PrP transgenic Drosophila
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